Reviewed by James Philip Dunn Jr., MD
An open-label extension of two pivotal clinical trials has given ophthalmologists critical, real-world evidence of the effectiveness of adalimumab as a treatment of noninfectious intermediate uveitis.
Optical coherence tomography angiography (OCTA) could play a growing role in the assessment of anterior inflammation from uveitis, according to results from a pilot study presented by Francesco Pichi, MD.
With the first ocular gene therapy approved in the United States, Szilard Kiss, MD, points out that the gene therapy era for retinal disease has arrived, “and hopefully it will arrive for age-related macular degeneration.”
Although the phase III Chroma and Spectri studies for lampalizumab (Genentech), an investigational compound for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD), failed to meet their primary endpoints, numerous lessons can be learned from the study data.